Amjevita, the first biosimilar competitor to Humira hit the U.S. market at the end of January. Showcasing the dysfunction of our healthcare delivery system, the copycat drug came to market with two drastically different list prices. One, a mere 5% discount relative to Humira and another with a 55% discount. Why two prices and who would pay for the more expensive option?
This Little Device Will Save your Health Plan Big Bucks
The Blockbuster Drug of our Lifetime Loses its Monopoly Status on January 1, 2023
In 2003, a little drug named Humira hit the market under the name DE27. Analysts believed at the time that Humira, which was approved to treat Rheumatoid Arthritis, would eventually generate between $500M and $1B in sales annually. In 2021, Humira’s global sales totaled $20.7B. Lifetime earnings have eclipsed $200B.
#BenefitsReimagined
We were recently asked what Benefits Reimagined means to us…
Benefits Reimagined means that someone uninsured can get their insulin delivered overnight for free. It means an expecting mother can deliver their child and not worry about affording their deductible because there isn’t one to pay. It means that a woman battling cancer can get the clinical care she needs without having to fight the insurance system that is working against her.
Delivering High Value Primary Care
Schaefer Autobody: How a Health Plan Tune-Up Led to $0 Deductibles
Faced once again with an increase in health plan costs, Schaefer Autobody knew they needed a change. They had grown more and more frustrated with their inability to control their healthcare spend and continue to provide great benefits to their team. Another 9% increase, despite two years of declining healthcare expenditures, just wasn’t going to cut it.
Saving for a Rainy Day: 39% of Americans Can’t Cover an Unplanned Expense
Healthcare: The Third Leading Cause of Death in the U.S.
It turns out that it’s far safer to jump out of an airplane than to access healthcare in the U.S. According to recent study by Johns Hopkins, more than 250,000 people in the United States die every year due to medical mistakes, making it the third-leading cause of death after heart disease and cancer.
How GoodRx Makes (A Lot) of Money
A Major Win Against Healthcare Fraud
On the Path to Fixing Healthcare Part 2 - Eliminating Rx Waste
This post is Part 2 in our series on Fixing Healthcare: Eliminating Rx Waste. Part 1 discussed Direct Contracting and can be read here. What if your business’s employee health plan was covering a drug that cost $350 when there was a comparable alternative that would cost you $13?
